MannKind Corporation announced April 1 that that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 13 to 1 to recommend that AFREZZA® (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be granted marketing approval by the FDA to improve glycemic control in adults with type 2 diabetes.

MannKind’s shares rose by more than 130% in evening trading after the Tuesday vote, reaching a four-year high of around $9.50 before settling down to open at $7.76 on Wednesday.

press release
article in FierceBiotech